Peptide Synthesis Using Segmented Protecting Groups

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for generating pharmaceutically relevant peptides are inefficient and lack specificity in producing desired compounds, leading to impurities and low yields.

Innovation Solution

A multi-step process involving reactions between specific compounds of formulas I-A, I-B, I-C, I-D, and I-E, or their salts, to form compound VIII or its salt, using coupling agents and amino protecting groups to achieve high purity and specificity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If current methods for generating pharmaceutically relevant peptides are used, then the process is simpler, but the efficiency and specificity are low leading to impurities and low yields

Engineering Contradiction:
Improvesynthesis efficiencyVSAvoidsynthesis specificity
Core Design Contradiction:
ProductivityVSManufacturing precision

Solution Approach 1:

The patent divides the peptide synthesis into multiple discrete steps with specific protecting group strategies. Each amino acid residue is introduced sequentially with controlled protection and deprotection steps, allowing high specificity at each stage while maintaining overall synthesis efficiency through systematic progression.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent employs pre-installed protecting groups on amino acid building blocks before coupling reactions. These protecting groups (such as Boc, Fmoc, Cbz) are strategically placed to prevent unwanted side reactions during synthesis, ensuring high specificity before the actual peptide bond formation occurs.

Inventive Principle:
Principle #10Preliminary action

2Quantity of substance

If current methods are used, then fewer reagents are required, but the yield and purity of the desired compound are low

Engineering Contradiction:
Improvecompound yieldVSAvoidcompound purity
Core Design Contradiction:
Quantity of substanceVSManufacturing precision

Solution Approach 1:

The patent uses coupling agents (such as HATU, HBTU, EDC) as intermediaries to facilitate peptide bond formation between amino acid residues. These coupling agents enable high-yield, high-specificity amide bond formation while minimizing side reactions, thereby simultaneously improving both yield and purity of the final peptide product.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent optimizes reaction parameters including solvent selection (DMF, DCM, NMP), temperature control, and stoichiometry of reagents to maximize both yield and purity. By carefully adjusting these parameters at each synthesis step, the method achieves high efficiency while maintaining excellent product quality.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The process enables the efficient and specific synthesis of compound VIII or its salt with high purity, reducing the need for purification methods like column chromatography and improving yield.

Implementation Method 1

reacting a compound of formula I-A or a salt thereof with a compound of formula I-B or a salt thereof to form a compound of formula I-C

Methodology Applied
Scientific EffectChemical Bonding: Chemical Bonding

Implementation Method 2

converting the compound of formula I-C to a compound of formula I-D wherein the amino protecting group Y1 is converted to an amino group

Methodology Applied
Scientific EffectAcid-mediated deprotection:

Implementation Method 3

reacting the compound of formula I-D or a salt thereof with a compound of formula I-E or a salt thereof to form the compound of formula VIII

Methodology Applied
Scientific EffectChemical Bonding: Chemical Bonding

Data Source

PatentUS20250002531A1Processes for preparing pharmaceutically relevant peptides
Publication Date: 2025.01.02 STEALTH BIOTHERAPEUTICS INC
  • US20250002531A1 patent drawing
  • US20250002531A1 patent drawing
  • US20250002531A1 patent drawing

AI summary

The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-2′6′-Dmt-Lys-Phe-NH2.